Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
The influence of mifepristone to caspase 3 expression in adenomyosis
1 Department of Obstetrics and Gynecology, Yantai Yuhuangding Hospital, Yantai (China)
Clin. Exp. Obstet. Gynecol. 2014, 41(2), 154–157; https://doi.org/10.12891/ceog15872014
Published: 10 April 2014
Objective: To discuss the influence of mifepristone to caspase 3 expression in adenomyosis tissue. Materials and Methods: Sixty patients were equally divided into four groups. Groups 1,2, and 3 were treated with 5, 10, and 15 mg mifepristone, respectively and group 4 was treated with placebo. The expression of caspase 3 was examined by immunohistochemical method in both eutopic and ectopic endometria of the 40 cases. Results: Compared with placebo group, the expression of caspase 3 in both eutopic endometrium and ectopic endometrium in the three treatment groups was significantly increased. There was no difference in the expression of caspase 3 in both eutopic and ectopic endometria between the ten and 25 mg treatment groups, while both the ten and 25 mg treatment groups had a higher expression intensity of caspase 3 in both eutopic and ectopic endometria, compared with the five mg treatment group (p < 0.01). Conclusion: Mifepristone can increase the expression of caspase 3 in both eutopic and ectopic endometria and initiate cell apoptosis in both eutopic and ectopic endometria. Therefore mifepristone can effectively inhibit the emergence and development of adenomyosis.